Podcast: Cybin CEO: Big Pharma Can No Longer Sit On The Sidelines In Psychedelics

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

Podcast: Doug Drysdale, CEO of Cybin, tells Scrip about the controversial history of psychedelics and their potential role in addressing mental health disorders. The CEO also weighs in on consolidation in the psychedelic sector, which is currently dominated by biotech, and claims big pharma can no longer sit on the sidelines.

Scrip Podcast Special
• Source: Alamy

It has been a busy time for psychedelic-based therapies. COMPASS Pathways revealed plans earlier this month to expand investigation of COMP360 to autistic adults, marking the first mechanistic study of the hallucinogen psilocybin in this population. Mind Medicine, Inc. announced promising efficacy data from a Phase II trial of LSD in anxiety disorders around the same time. Meanwhile, Cybin Inc. engaged a CRO for a Phase I/II study of its lead candidate, CYB003, which is penned to start in the middle of the year. (Also see "Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety" - Scrip, 24 November, 2021.)

These milestones mark a big shift from how psychedelic compounds were viewed half a century ago, according to Cybin CEO...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 
• By Andrew McConaghie

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1

 
• By Saba Afreen

As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.